Few individuals can successfully combine an inventor's creativity with an entrepreneur's business acumen to launch a device start-up company. Doing that nearly a dozen times, as Stuart Edwards has, is quite a feat, particularly in today's hostile environment for device company creation. Edwards has a unique formula, relying on a common technology base (radio frequency or RF energy) which he applies to untapped markets, such as sleep and gastrointestinal disorders. Critics of his unorthodox approach claim Edwards fails to maximize value, creating separate companies rather than building a single company with greater critical mass. But Edwards has yet to have a company fail and investors are returning for more.
by Stephen Levin
It's not immediately apparent upon meeting Stuart Edwards, a mild-mannered, British born and educated engineer who remains among the few...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Ellipsis said it will use its new funding to expand its AI-powered voice assistant Sage across health systems. Ellipsis is part of the global vocal biomarker market, which is expected to exceed $9bn by the end of 2033, according to a research market report.
After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.
European venture capital firm Sofinnova Partners’ portfolio companies BioCorteX, Bioptimus, Cure51 and Latent Labs will benefit from the investor’s new partnership with tech giant NVIDIA.
The $10m seed extension funding round will be used to launch the second-generation wearable headband with the added SmartSleep AI operating system.
The $10m seed extension funding round will be used to launch the second-generation wearable headband with the added SmartSleep AI operating system.
Despite near-term cost pressures, Intuitive Surgical is expanding manufacturing and R&D in North America and Europe to meet demand for Ion, X and Xi systems.
Capital remains available for good healthtech projects, but it is more concentrated and harder to find than of late. Founders and inventors must know how to unlock it. The BioWales 2025 investor panel told them where they could be going wrong.
